Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis (Q26770823)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis	scientific article

Statements

scholarly article

0 references

Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis (English)

0 references

multiple sclerosis

0 references

1 reference

based on heuristic

inferred from title

author name string

Uwe K Zettl

1

0 references

Paulus Rommer

2

0 references

Petra Hipp

3

0 references

Robert Patejdl

4

0 references

language of work or name

0 references

publication date

January 2016

0 references

Therapeutic advances in neurological disorders

1 reference

9

0 references

1

0 references

9-30

0 references

Cannabinoid pharmacology: the first 66 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

7 April 2017

Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

7 April 2017

Causal association between cannabis and psychosis: examination of the evidence

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

7 April 2017

Treatments for spasticity and pain in multiple sclerosis: a systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

7 April 2017

Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

7 April 2017

Endocannabinoids control spasticity in a multiple sclerosis model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

7 April 2017

Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Linguistic and psychometric validation of the MSSS-88 questionnaire for patients with multiple sclerosis and spasticity in Germany

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Nabiximols (THC/CBD oromucosal spray, Sativex®) in clinical practice--results of a multicenter, non-interventional study (MOVE 2) in patients with multiple sclerosis spasticity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Pathology of multiple sclerosis and related inflammatory demyelinating diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Natural history of multiple sclerosis symptoms

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Costs and quality of life in multiple sclerosis patients with spasticity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Troublesome symptoms in cancer survivors: fatigue, insomnia, neuropathy, and pain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Multiple sclerosis review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

The unique features of traumatic brain injury in children. Review of the characteristics of the pediatric skull and brain, mechanisms of trauma, patterns of injury, complications and their imaging findings--part 1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Immune-mediated CNS diseases: a review on nosological classification and clinical features

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Neuropharmacology and therapeutic potential of cannabinoids

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

National MS registries

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Emerging strategies for exploiting cannabinoid receptor agonists as medicines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

The contribution of cognition and spasticity to driving performance in multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc analysis of a randomized, double-blind, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Managing neuropathic pain with Sativex: a review of its pros and cons

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Endocannabinoids and the regulation of their levels in health and disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Combined cannabinoid therapy via an oromucosal spray

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Managing the symptoms of multiple sclerosis: a multimodal approach

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Botulinum toxin in patients with multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Neurophysiological methods for the assessment of spasticity: the Hoffmann reflex, the tendon reflex, and the stretch reflex

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Biomechanical approaches applied to the lower and upper limb for the measurement of spasticity: a systematic review of the literature.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Clinical scales for the assessment of spasticity, associated phenomena, and function: a systematic review of the literature.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Anti-spasticity agents for multiple sclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Psychiatric effects of cannabis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

The surgical treatment of spasticity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Pharmacology of cannabinoid receptor ligands.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 September 2017

A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

31 May 2018

Cognitive functioning of long-term heavy cannabis users seeking treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

31 May 2018

Spasticity in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1756285615612659

21 January 2018

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1756285615612659

21 January 2018

Driving performance in persons with mild to moderate symptoms of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1756285615612659

21 January 2018

Advances in the management of MS spasticity: recent observational studies

1 reference

https://api.crossref.org/works/10.1177%2F1756285615612659

21 January 2018

Spasticity in patients with multiple sclerosis--clinical characteristics, treatment and quality of life

1 reference

https://api.crossref.org/works/10.1177%2F1756285615612659

21 January 2018

Stop using the Ashworth Scale for the assessment of spasticity.

1 reference

https://api.crossref.org/works/10.1177%2F1756285615612659

21 January 2018

Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability

1 reference

https://api.crossref.org/works/10.1177%2F1756285615612659

21 January 2018

Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish

1 reference

https://api.crossref.org/works/10.1177%2F1756285615612659

21 January 2018

Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain

1 reference

https://api.crossref.org/works/10.1177%2F1756285615612659

21 January 2018

Prevalence and treatment of spasticity reported by multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1177%2F1756285615612659

21 January 2018

A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment.

1 reference

https://api.crossref.org/works/10.1177%2F1756285615612659

21 January 2018

Rehabilitation in practice: Spasticity management

1 reference

https://api.crossref.org/works/10.1177%2F1756285615612659

21 January 2018

A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray.

1 reference

https://api.crossref.org/works/10.1177%2F1756285615612659

21 January 2018

A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray.

1 reference

https://api.crossref.org/works/10.1177%2F1756285615612659

21 January 2018

MObility ImproVEment with spasticity in multiple sclerosis in Europe: the MOVE 1 EU study

1 reference

https://api.crossref.org/works/10.1177%2F1756285615612659

21 January 2018

The medicinal use of cannabis in the UK: results of a nationwide survey.

1 reference

https://api.crossref.org/works/10.1177%2F1756285615612659

21 January 2018

Burden of disease in multiple sclerosis patients with spasticity in Germany: mobility improvement study (Move I).

1 reference

https://api.crossref.org/works/10.1177%2F1756285615612659

21 January 2018

Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1756285615612659

21 January 2018

Effects of intrathecal triamincinolone-acetonide treatment in MS patients with therapy-resistant spasticity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 November 2018

A pilot study of a comparison between a patient scored numeric rating scale and clinician scored measures of spasticity in multiple sclerosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 November 2018

Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4710104

28 November 2018

Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society

1 reference

https://pubmed.ncbi.nlm.nih.gov/26788128

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sativex® in multiple sclerosis spasticity: a cost-effectiveness model

1 reference

https://pubmed.ncbi.nlm.nih.gov/26788128

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26788128

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PRELIMINARY TRIAL OF CARISOPRODOL IN MULTIPLE SCLEROSIS

1 reference

https://pubmed.ncbi.nlm.nih.gov/26788128

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Spasticity in multiple sclerosis: results of a patient survey

1 reference

https://pubmed.ncbi.nlm.nih.gov/26788128

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity

1 reference

https://pubmed.ncbi.nlm.nih.gov/26788128

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use

1 reference

https://pubmed.ncbi.nlm.nih.gov/26788128

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intrathecal baclofen for severe spinal spasticity

1 reference

https://pubmed.ncbi.nlm.nih.gov/26788128

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The therapeutic value of cannabinoids in MS: real or imaginary?

1 reference

https://pubmed.ncbi.nlm.nih.gov/26788128

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stop using the Ashworth scale for the assessment of spasticity

1 reference

https://pubmed.ncbi.nlm.nih.gov/26788128

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interrater reliability of a modified Ashworth scale of muscle spasticity

1 reference

https://pubmed.ncbi.nlm.nih.gov/26788128

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1177/1756285615612659

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q26770823&oldid=1973984578"